RecruitingPhase 2NCT07187375

Pharmacokinetics, Safety and Tolerability of Crinecerfont in Participants With Congenital Adrenal Hyperplasia Who Are Less Than 2 Years Old

A Phase 2, Open-Label Study to Evaluate the Pharmacokinetics, Safety, Tolerability, and Pharmacodynamics of Crinecerfont in Pediatric Subjects 0 to <2 Years of Age With Congenital Adrenal Hyperplasia

Sponsor

Neurocrine Biosciences

Enrollment

6 participants

Start Date

Sep 30, 2025

Study Type

INTERVENTIONAL

Conditions

Congenital Adrenal Hyperplasia

Summary

The main objective for this study is to evaluate the pharmacokinetics (PK) of crinecerfont in pediatric participants 0 to \<2 years of age with congenital adrenal hyperplasia (CAH).

Eligibility

Min Age: 0 YearsMax Age: 23 Months

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called Crinecerfont for people with congenital adrenal hyperplasia. The study is currently recruiting participants at 3 locations. People eligible for this study include aged 0 Years to 23 Months.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.